Search

Displaying results 4241 - 4250 of 7186 in total
  1. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    [L42325] Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. … Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.[A36741]

  2. Drug

    PHB-050

    go.drugbank.com/drugs/DB32061
    Experimental

    PHB-050 is a novel, next-generation anti-IgE antibody designed to block IgE from binding to mast cells, while also rapidly reducing circulating IgE and inhibiting its production.

  3. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components.

    Synonyms: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
  4. Drug

    Basic Fibroblast Growth Factor

    go.drugbank.com/drugs/DB14131
    Investigational

    Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. … It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (Fibroblast Growth Factor 1).

  5. Drug

    Nalorphine

    go.drugbank.com/drugs/DB11490
    ExperimentalVet approved

    It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence. … It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics.

  6. Drug

    Inosine pranobex

    go.drugbank.com/drugs/DB13156
    Approved

    Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.

  7. Drug

    Genistein

    go.drugbank.com/drugs/DB01645
    Investigational

    An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. … It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].

  8. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  9. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).

  10. Drug

    6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one

    go.drugbank.com/drugs/DB08267
    Experimental

    Stilbenes (C6-C2-C6) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. … It is known to target queuine tRNA-ribosyltransferase.